11/14/2024
6:15 PM | ASLAN Pharmaceuticals (Subject)
Lind Global Fund II LP (Filed by)
| Form SC 13G | |
09/06/2024
6:41 AM | ASLAN Pharmaceuticals (Subject)
Nasdaq Stock Market LLC (Filed by)
| Form 25-NSE | |
08/08/2024
10:36 AM | ASLAN Pharmaceuticals (Subject)
UBS Group AG (Filed by)
| Form SCHEDULE 13G/A | |
07/17/2024
6:29 AM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/15/2024
6:29 AM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/23/2024
11:15 PM | ASLAN Pharmaceuticals (Filer)
| Form EFFECT | |
06/14/2024
3:46 PM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
|
06/14/2024
3:30 PM | ASLAN Pharmaceuticals (Subject)
JPMorgan Chase Bank, N.A. - ADR Depositary (Filed by)
| Form F-6 POS | |
06/12/2024
3:32 PM | ASLAN Pharmaceuticals (Filer)
| Form F-3
Registration statement for securities of certain foreign private issuers | |
05/09/2024
6:10 AM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/07/2024
6:41 AM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/22/2024
7:29 AM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/12/2024
7:15 AM | ASLAN Pharmaceuticals (Filer)
| Form 424B5 | |
04/12/2024
7:10 AM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/12/2024
5:37 AM | ASLAN Pharmaceuticals (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
04/12/2024
5:27 AM | ASLAN Pharmaceuticals (Filer)
| Form 20-F
Registration statement / Annual report / Transition report | |
04/12/2024
5:05 AM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/31/2024
11:15 PM | ASLAN Pharmaceuticals (Filer)
| Form EFFECT | |
03/28/2024
1:11 PM | ASLAN Pharmaceuticals (Filer)
| Form D
Notice of Exempt Offering of Securities | |
03/21/2024
3:42 PM | ASLAN Pharmaceuticals (Subject)
INTRACOASTAL CAPITAL, LLC (Filed by)
| Form SC 13G | |
03/14/2024
5:24 AM | ASLAN Pharmaceuticals (Filer)
| Form 424B5 | |
03/13/2024
6:27 AM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/11/2024
7:03 AM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/14/2024
3:45 PM | ASLAN Pharmaceuticals (Subject)
K2 HealthVentures Equity Trust LLC (Filed by)
| Form SC 13G/A | |
02/14/2024
9:22 AM | ASLAN Pharmaceuticals (Subject)
BIOTECHNOLOGY VALUE FUND L P (Filed by)
| Form SC 13G/A | |
02/06/2024
9:38 AM | ASLAN Pharmaceuticals (Subject)
UBS Group AG (Filed by)
| Form SC 13G | |
01/24/2024
6:52 AM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/08/2024
6:02 AM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/22/2023
3:24 PM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/08/2023
3:42 PM | ASLAN Pharmaceuticals (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
